Viatris Inc. buy marge
Start price
07.08.17
/
50%
€28.97
Target price
25.06.19
€46.64
Performance (%)
-44.08%
End price
25.06.19
€16.20
Summary
This prediction ended on 25.06.19 with a price of €16.20. The BUY prediction by marge for Viatris Inc. performed very badly with a performance of -44.08%. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Viatris Inc. | 2.319% | 2.319% | 27.748% | -2.630% |
| iShares Core DAX® | 2.594% | -1.861% | 13.242% | 16.867% |
| iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% | 45.898% |
| iShares Nikkei 225® | 0.687% | -8.704% | 17.510% | 2.760% |
| iShares S&P 500 | 2.209% | -1.988% | 27.632% | 42.955% |
Comments by marge for this prediction
In the thread Viatris Inc. diskutieren
MYL is extremely attractively priced.
The company has generated real robust and consistent free cash flow that only looks like it will continue to grow moving forward, and I think now is as good a time as ever to remind investors that MYL is a very different company than traditional generic companies like TEVA and specialty pharmaceutical companies like Valeant (VRX). For one, MYL has a significantly diverse product line that encompasses thousands of generics both domestically and internationally, making the company's cash flow relatively safe and risk adverse.
Even heading into the earnings report I am confident that the stock is attractively priced based on the market misconstruing the TEVA news and its effect on MYL going forward.
(Laufzeit überschritten)